Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 251
Filter
1.
Aging (Albany NY) ; 16(10): 8810-8821, 2024 May 20.
Article in English | MEDLINE | ID: mdl-38771141

ABSTRACT

BACKGROUND: The purpose of this prospective study was to evaluate the association of systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI), with PSCI in patients with acute ischemic stroke (AIS). METHODS: First-onset AIS patients were consecutively included from January 1, 2022 to March 1, 2023. The baseline information was collected at admission. Fasting blood was drawn the next morning. Cognitive function was assessed by the Montreal Cognitive Assessment (MoCA) 3 months after onset. Logistic regression analysis was performed to explore the correlation between SII, SIRI, and PSCI. Receiver operating characteristic (ROC) was conducted to evaluate the predictive ability of SII. RESULTS: 332 participants were recruited, and 193 developed PSCI. Compared with patients without PSCI, the patients with PSCI had higher SII (587.75 (337.42, 988.95) vs. 345.66 (248.44, 572.89), P<0.001) and SIRI (1.59 (0.95, 2.84) vs. 1.02 (0.63, 1.55), P=0.007). SII and SIRI negatively correlated with MoCA scores (both P<0.05). The multivariable logistic regression analysis indicated that SII was independently associated with PSCI (P<0.001), while SIRI was not. The optimal cutoff for SII to predict PSCI was 676.83×109/L. CONCLUSIONS: A higher level of SII upon admission was independently correlated to PSCI three months later in AIS patients.


Subject(s)
Cognitive Dysfunction , Inflammation , Ischemic Stroke , Humans , Male , Female , Ischemic Stroke/immunology , Ischemic Stroke/complications , Ischemic Stroke/blood , Cognitive Dysfunction/etiology , Cognitive Dysfunction/blood , Cognitive Dysfunction/immunology , Aged , Middle Aged , Prospective Studies , Inflammation/immunology , Inflammation/blood , Mental Status and Dementia Tests
2.
Mol Neurodegener ; 19(1): 38, 2024 Apr 24.
Article in English | MEDLINE | ID: mdl-38658964

ABSTRACT

BACKGROUND: Alzheimer's disease (AD) is the most frequent cause of dementia. Recent evidence suggests the involvement of peripheral immune cells in the disease, but the underlying mechanisms remain unclear. METHODS: We comprehensively mapped peripheral immune changes in AD patients with mild cognitive impairment (MCI) or dementia compared to controls, using cytometry by time-of-flight (CyTOF). RESULTS: We found an adaptive immune signature in AD, and specifically highlight the accumulation of PD1+ CD57+ CD8+ T effector memory cells re-expressing CD45RA in the MCI stage of AD. In addition, several innate and adaptive immune cell subsets correlated to cerebrospinal fluid (CSF) biomarkers of AD neuropathology and measures for cognitive decline. Intriguingly, subsets of memory T and B cells were negatively associated with CSF biomarkers for tau pathology, neurodegeneration and neuroinflammation in AD patients. Lastly, we established the influence of the APOE ε4 allele on peripheral immunity. CONCLUSIONS: Our findings illustrate significant peripheral immune alterations associated with both early and late clinical stages of AD, emphasizing the necessity for further investigation into how these changes influence underlying brain pathology.


Subject(s)
Adaptive Immunity , Alzheimer Disease , Cognitive Dysfunction , Disease Progression , Humans , Alzheimer Disease/immunology , Alzheimer Disease/cerebrospinal fluid , Aged , Male , Cognitive Dysfunction/immunology , Female , Adaptive Immunity/immunology , Biomarkers/cerebrospinal fluid , Aged, 80 and over , Middle Aged
3.
Mult Scler Relat Disord ; 85: 105596, 2024 May.
Article in English | MEDLINE | ID: mdl-38574722

ABSTRACT

Clinicians are becoming increasingly aware of the cognitive and psychopathological consequences of neurological diseases, which were once thought to manifest with motor and sensory impairments only. The cognitive profile of multiple sclerosis, in particular, is now well-characterised. Similar efforts are being made to better characterise the cognitive profile of other central nervous system inflammatory demyelinating autoimmune disorders. This review discusses the current understanding of the cognitive and psychological features of neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Detailed analysis of the cognitive sequelae of the above conditions can not only assist with understanding disease pathogenesis but also can guide appropriate management of the symptoms and consequently, improve the quality of life and long-term outcomes for these patients. This narrative review will also identify research gaps and provide recommendations for future directions in the field.


Subject(s)
Myelin-Oligodendrocyte Glycoprotein , Neuromyelitis Optica , Humans , Neuromyelitis Optica/immunology , Myelin-Oligodendrocyte Glycoprotein/immunology , Cognitive Dysfunction/etiology , Cognitive Dysfunction/immunology , Autoantibodies/immunology
4.
Epilepsia ; 65(5): 1475-1487, 2024 May.
Article in English | MEDLINE | ID: mdl-38470097

ABSTRACT

OBJECTIVE: We previously demonstrated that interleukin-1 receptor-mediated immune activation contributes to seizure severity and memory loss in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. In the present study, we assessed the role of the myeloid differentiation primary response gene 88 (MyD88), an adaptor protein in Toll-like receptor signaling, in the key phenotypic characteristics of anti-NMDAR encephalitis. METHODS: Monoclonal anti-NMDAR antibodies or control antibodies were infused into the lateral ventricle of MyD88 knockout mice (MyD88-/-) and control C56BL/6J mice (wild type [WT]) via osmotic minipumps for 2 weeks. Seizure responses were measured by electroencephalography. Upon completion of the infusion, the motor, anxiety, and memory functions of the mice were assessed. Astrocytic (glial fibrillary acidic protein [GFAP]) and microglial (ionized calcium-binding adaptor molecule 1 [Iba-1]) activation and transcriptional activation for the principal inflammatory mediators involved in seizures were determined using immunohistochemistry and quantitative real-time polymerase chain reaction, respectively. RESULTS: As shown before, 80% of WT mice infused with anti-NMDAR antibodies (n = 10) developed seizures (median = 11, interquartile range [IQR] = 3-25 in 2 weeks). In contrast, only three of 14 MyD88-/- mice (21.4%) had seizures (0, IQR = 0-.25, p = .01). The WT mice treated with antibodies also developed memory loss in the novel object recognition test, whereas such memory deficits were not apparent in MyD88-/- mice treated with anti-NMDAR antibodies (p = .03) or control antibodies (p = .04). Furthermore, in contrast to the WT mice exposed to anti-NMDAR antibodies, the MyD88-/- mice had a significantly lower induction of chemokine (C-C motif) ligand 2 (CCL2) in the hippocampus (p = .0001, Sidak tests). There were no significant changes in the expression of GFAP and Iba-1 in the MyD88-/- mice treated with anti-NMDAR or control antibodies. SIGNIFICANCE: These findings suggest that MyD88-mediated signaling contributes to the seizure and memory phenotype in anti-NMDAR encephalitis and that CCL2 activation may participate in the expression of these features. The removal of MyD88 inflammation may be protective and therapeutically relevant.


Subject(s)
Anti-N-Methyl-D-Aspartate Receptor Encephalitis , Myeloid Differentiation Factor 88 , Seizures , Signal Transduction , Animals , Male , Mice , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/immunology , Calcium-Binding Proteins/metabolism , Cognitive Dysfunction/metabolism , Cognitive Dysfunction/immunology , Cognitive Dysfunction/etiology , Disease Models, Animal , Electroencephalography , Glial Fibrillary Acidic Protein/metabolism , Mice, Inbred C57BL , Mice, Knockout , Microfilament Proteins/metabolism , Myeloid Differentiation Factor 88/genetics , Myeloid Differentiation Factor 88/metabolism , Seizures/metabolism , Seizures/immunology , Signal Transduction/physiology
5.
Cells ; 12(13)2023 06 28.
Article in English | MEDLINE | ID: mdl-37443769

ABSTRACT

The term 'perinatal environment' refers to the period surrounding birth, which plays a crucial role in brain development. It has been suggested that dynamic communication between the neuro-immune system and gut microbiota is essential in maintaining adequate brain function. This interaction depends on the mother's status during pregnancy and/or the newborn environment. Here, we show experimental and clinical evidence that indicates that the perinatal period is a critical window in which stress-induced immune activation and altered microbiota compositions produce lasting behavioral consequences, although a clear causative relationship has not yet been established. In addition, we discuss potential early treatments for preventing the deleterious effect of perinatal stress exposure. In this sense, early environmental enrichment exposure (including exercise) and melatonin use in the perinatal period could be valuable in improving the negative consequences of early adversities. The evidence presented in this review encourages the realization of studies investigating the beneficial role of melatonin administration and environmental enrichment exposure in mitigating cognitive alteration in offspring under perinatal stress exposure. On the other hand, direct evidence of microbiota restoration as the main mechanism behind the beneficial effects of this treatment has not been fully demonstrated and should be explored in future studies.


Subject(s)
Brain-Gut Axis , Brain , Cognitive Dysfunction , Maternal Exposure , Prenatal Exposure Delayed Effects , Stress, Psychological , Cognitive Dysfunction/immunology , Cognitive Dysfunction/microbiology , Cognitive Dysfunction/prevention & control , Humans , Female , Animals , Prenatal Exposure Delayed Effects/etiology , Melatonin/administration & dosage , Brain/growth & development , Neurogenesis , Antioxidants/administration & dosage , Probiotics/administration & dosage
6.
Semin Arthritis Rheum ; 58: 152131, 2023 02.
Article in English | MEDLINE | ID: mdl-36527929

ABSTRACT

OBJECTIVES: To compare the magnitude of cognitive impairment against age-expected levels across the immune mediated inflammatory diseases (IMIDs: systemic lupus erythematosus [SLE], rheumatoid arthritis [RA], axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], psoriasis [PsO]). METHODS: A pre-defined search strategy was implemented in Medline, Embase and Psychinfo on 29/05/2021. Inclusion criteria were: (i) observational studies of an IMID, (ii) healthy control comparison, (iii) measuring cognitive ability (overall, memory, complex attention/executive function, language/verbal fluency), and (iv) sufficient data for meta-analysis. Standardised mean differences (SMD) in cognitive assessments between IMIDs and controls were pooled using random-effects meta-analysis. IMIDs were compared using meta-regression. RESULTS: In total, 65 IMID groups were included (SLE: 39, RA: 19, axSpA: 1, PsA: 2 PsO: 4), comprising 3141 people with IMIDs and 9333 controls. People with IMIDs had impairments in overall cognition (SMD: -0.57 [95% CI -0.70, -0.43]), complex attention/executive function (SMD -0.57 [95% CI -0.69, -0.44]), memory (SMD -0.55 [95% CI -0.68, -0.43]) and language/verbal fluency (SMD -0.51 [95% CI -0.68, -0.34]). People with RA and people with SLE had similar magnitudes of cognitive impairment in relation to age-expected levels. People with neuropsychiatric SLE had larger impairment in overall cognition compared with RA. CONCLUSIONS: People with IMIDs have moderate impairments across a range of cognitive domains. People with RA and SLE have similar magnitudes of impairment against their respective age-expected levels, calling for greater recognition of cognitive impairment in both conditions. To further understand cognition in the IMIDs, more large-scale, longitudinal studies are needed.


Subject(s)
Arthritis , Cognitive Dysfunction , Lupus Erythematosus, Systemic , Psoriasis , Humans , Arthritis, Psoriatic/complications , Arthritis, Psoriatic/immunology , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/immunology , Cognition , Cognitive Dysfunction/etiology , Cognitive Dysfunction/immunology , Lupus Erythematosus, Systemic/complications , Axial Spondyloarthritis/complications , Axial Spondyloarthritis/immunology , Arthritis/complications , Arthritis/immunology , Inflammation/complications , Inflammation/immunology
7.
Ann Clin Transl Neurol ; 10(2): 276-291, 2023 02.
Article in English | MEDLINE | ID: mdl-36579400

ABSTRACT

OBJECTIVE: Despite successful endovascular therapy, a proportion of stroke patients exhibit long-term functional decline, regardless of the cortical reperfusion. Our objective was to evaluate the early activation of the adaptive immune response and its impact on neurological recovery in patients with large vessel occlusion (LVO). METHODS: Nineteen (13 females, 6 males) patients with acute LVO were enrolled in a single-arm prospective cohort study. During endovascular therapy (EVT), blood samples were collected from pre and post-occlusion, distal femoral artery, and median cubital vein (controls). Cytokines, chemokines, cellular and functional profiles were evaluated with immediate and follow-up clinical and radiographic parameters, including cognitive performance and functional recovery. RESULTS: In the hyperacute phase (within hours), adaptive immune activation was observed in the post-occlusion intra-arterial environment (post). Ischemic vascular tissue had a significant increase in T-cell-related cytokines, including IFN-γ and MMP-9, while GM-CSF, IL-17, TNF-α, IL-6, MIP-1a, and MIP-1b were decreased. Cellularity analysis revealed an increase in inflammatory IL-17+ and GM-CSF+ helper T-cells, while natural killer (NK), monocytes and B-cells were decreased. A correlation was observed between hypoperfused tissue, infarct volume, inflammatory helper, and cytotoxic T-cells. Moreover, helper and cytotoxic T-cells were also significantly increased in patients with improved motor function at 3 months. INTERPRETATION: We provide evidence of the activation of the inflammatory adaptive immune response during the hyperacute phase and the association of pro-inflammatory cytokines with greater ischemic tissue and worsening recovery after successful reperfusion. Further characterization of these immune pathways is warranted to test selective immunomodulators during the early stages of stroke rehabilitation.


Subject(s)
Brain Ischemia , Cognitive Dysfunction , Motor Skills Disorders , Female , Humans , Male , Cytokines , Granulocyte-Macrophage Colony-Stimulating Factor , Immunity , Interleukin-17 , Prospective Studies , Stroke/complications , Stroke/immunology , Stroke/therapy , Brain Ischemia/complications , Brain Ischemia/immunology , Brain Ischemia/therapy , Cognitive Dysfunction/etiology , Cognitive Dysfunction/immunology , Motor Skills Disorders/etiology , Motor Skills Disorders/immunology , Neuroinflammatory Diseases/immunology
8.
Int Immunopharmacol ; 113(Pt A): 109375, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36461592

ABSTRACT

BACKGROUND: Recent studies have uncovered that hyperuricemia (HUA) leads to cognitive deficits, which are accompanied by neuronal damage and neuroinflammation. Here, we aim to explore the role of methyltransferase-like 3 (METTL3) in HUA-mediated neuronal apoptosis and microglial inflammation. METHODS: A HUA mouse model was constructed. The spatial memory ability of the mice was assessed by the Morris water maze experiment (MWM), and neuronal apoptosis was analyzed by the TdT-mediated dUTP nick end labeling (TUNEL) assay. Besides, enzyme-linked immunosorbent assay (ELISA) was utilized to measure the contents of inflammatory factors (IL-1ß, IL-6, and TNF-α) and oxidative stress markers (MDA, SOD, and CAT) in the serum of mice. In vitro, the mouse hippocampal neuron (HT22) and microglia (BV2) were treated with uric acid (UA). Flow cytometry was applied to analyze HT22 and BV2 cell apoptosis, and ELISA was conducted to observe neuroinflammation and oxidative stress. In addition, the expression of MyD88, p-NF-κB, NF-κB, NLRP3, ASC and Caspase1 was determined by Western blot. RESULTS: METTL3 and miR-124-3p were down-regulated, while the MyD88-NF-κB pathway was activated in the HUA mouse model. UA treatment induced neuronal apoptosis in HT22 and stimulated microglial activation in BV2. Overexpressing METTL3 alleviated HT22 neuronal apoptosis and resisted the release of inflammatory cytokines and oxidative stress mediators in BV2 cells. METTL3 repressed MyD88-NF-κB and NLRP3-ASC-Caspase1 inflammasome. In addition, METTL3 overexpression enhanced miR-124-3p expression, while METTL3 knockdown aggravated HT22 cell apoptosis and BV2 cell overactivation. CONCLUSION: METTL3 improves neuronal apoptosis and microglial activation in the HUA model by choking the MyD88/NF-κB pathway and up-regulating miR-124-3p.


Subject(s)
Cognitive Dysfunction , Hyperuricemia , Inflammasomes , Methyltransferases , Animals , Mice , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/immunology , CARD Signaling Adaptor Proteins/genetics , CARD Signaling Adaptor Proteins/immunology , Caspase 1/genetics , Caspase 1/immunology , Cells, Cultured , Cognitive Dysfunction/etiology , Cognitive Dysfunction/genetics , Cognitive Dysfunction/immunology , Disease Models, Animal , Hyperuricemia/complications , Hyperuricemia/genetics , Hyperuricemia/immunology , Inflammasomes/genetics , Inflammasomes/immunology , Methyltransferases/genetics , Methyltransferases/immunology , MicroRNAs/genetics , MicroRNAs/immunology , Myeloid Differentiation Factor 88/genetics , Myeloid Differentiation Factor 88/immunology , Nervous System/drug effects , Nervous System/immunology , Nervous System/physiopathology , Neuroinflammatory Diseases/etiology , Neuroinflammatory Diseases/genetics , Neuroinflammatory Diseases/immunology , NF-kappa B , NF-kappa B p50 Subunit/genetics , NF-kappa B p50 Subunit/immunology , NLR Family, Pyrin Domain-Containing 3 Protein/genetics , NLR Family, Pyrin Domain-Containing 3 Protein/immunology , Uric Acid/administration & dosage , Uric Acid/adverse effects , Uric Acid/pharmacology
9.
Brain Res Bull ; 181: 36-45, 2022 04.
Article in English | MEDLINE | ID: mdl-35066097

ABSTRACT

Ischemia in the medial prefrontal cortex (mPFC) causes cognitive impairment in stroke cases. This study aimed to examine the effects of varenicline as α7 and α4ß2 nicotine acetylcholine receptors (nAChRs) agonist, on cognitive impairment, inflammation, apoptosis, and synaptic dysfunction in mPFC ischemia. Mice were divided to three groups of control, sham, or photothrombotic mPFC ischemia model. The control and sham groups received 2 ml/kg of normal saline for a 14-day period. As well, the animals in the ischemia groups received normal saline (2 ml/kg) or varenicline at 0.1, 1, and 3 mg/kg doses for a 14-day period. Anxiety-like behaviors were then assessed by open field (OFT) and elevated plus-maze (EPM) tests. Memory was also evaluated using Morris water maze (MWM) and novel object recognition (NOR) tests. The levels of inflammatory (IL-1ß, TNF-α), apoptotic (Bax, caspase3, BCL-2), and synaptic (SYP, PSD-95, and GAP-43) proteins were examined using the western blot method. In addition, the histological evaluation was performed to assess tissue damage. The administration of Varenicline at the dose of 3 mg/kg reduced the IL-1ß, TNF-α, Bax, and caspase3 levels. Moreover, it increased BCL-2, SYP, PSD-95, and GAP-43 levels at the same dose and ameliorated memory impairment and anxiety-like behaviors in mPFC ischemic mice. Varenicline improved cognitive impairment by blocking inflammation and apoptosis, improving synaptic factors, and diminishing tissue damage in the mPFC ischemic mice.


Subject(s)
Apoptosis/drug effects , Brain Ischemia/complications , Cognitive Dysfunction/drug therapy , Neuroinflammatory Diseases/drug therapy , Nicotinic Agonists/pharmacology , Prefrontal Cortex/drug effects , Synapses/drug effects , Varenicline/pharmacology , Animals , Anxiety/drug therapy , Anxiety/etiology , Behavior, Animal/drug effects , Brain Ischemia/immunology , Brain Ischemia/metabolism , Brain Ischemia/physiopathology , Cognitive Dysfunction/immunology , Cognitive Dysfunction/metabolism , Cognitive Dysfunction/physiopathology , Disease Models, Animal , Mice , Neuroinflammatory Diseases/immunology , Neuroinflammatory Diseases/metabolism , Neuroinflammatory Diseases/physiopathology , Nicotinic Agonists/administration & dosage , Prefrontal Cortex/immunology , Prefrontal Cortex/metabolism , Prefrontal Cortex/physiopathology , Synapses/metabolism , Varenicline/administration & dosage
10.
Sci Rep ; 12(1): 1312, 2022 01 25.
Article in English | MEDLINE | ID: mdl-35079008

ABSTRACT

Autoantibodies are self-antigen reactive antibodies that play diverse roles in the normal immune system, tissue homeostasis, and autoimmune and neurodegenerative diseases. Anti-neuronal autoantibodies have been detected in neurodegenerative disease serum, with unclear significance. To identify diagnostic biomarkers of Alzheimer's disease (AD), we analyzed serum autoantibody profiles of the HuProt proteome microarray using the discovery set of cognitively normal control (NC, n = 5) and AD (n = 5) subjects. Approximately 1.5-fold higher numbers of autoantibodies were detected in the AD group (98.0 ± 39.9/person) than the NC group (66.0 ± 39.6/person). Of the autoantigen candidates detected in the HuProt microarray, five autoantigens were finally selected for the ELISA-based validation experiment using the validation set including age- and gender-matched normal (NC, n = 44), mild cognitive impairment (MCI, n = 44) and AD (n = 44) subjects. The serum levels of four autoantibodies including anti-ATCAY, HIST1H3F, NME7 and PAIP2 IgG were significantly different among NC, MCI and/or AD groups. Specifically, the anti-ATCAY autoantibody level was significantly higher in the AD (p = 0.003) and MCI (p = 0.015) groups compared to the NC group. The anti-ATCAY autoantibody level was also significantly correlated with neuropsychological scores of MMSE (rs = - 0.229, p = 0.012), K-MoCA (rs = - 0.270, p = 0.003), and CDR scores (rs = 0.218, p = 0.016). In addition, a single or combined occurrence frequency of anti-ATCAY and anti-PAIP2 autoantibodies was significantly associated with the risk of MCI and AD. This study indicates that anti-ATCAY and anti-PAIP2 autoantibodies could be a potential diagnostic biomarker of AD.


Subject(s)
Alzheimer Disease/blood , Alzheimer Disease/immunology , Autoantibodies/blood , Cognitive Dysfunction/blood , Cognitive Dysfunction/immunology , Aged , Aged, 80 and over , Alzheimer Disease/epidemiology , Autoantibodies/immunology , Biomarkers/blood , Case-Control Studies , Cognitive Dysfunction/epidemiology , Cohort Studies , Female , Humans , Immunoglobulin G/blood , Immunoglobulin G/immunology , Male , Proteome , Republic of Korea/epidemiology , Risk Factors
11.
J Neuroimmunol ; 362: 577769, 2022 01 15.
Article in English | MEDLINE | ID: mdl-34871864

ABSTRACT

Cancer-related cognitive decline (CRCD) is a clinically important problem and negatively affects daily functioning and quality of life. We conducted a pilot longitudinal study from pre- to post-chemotherapy in patients with breast cancer to assess changes in inflammation and cognition over time, as well as the impact of baseline cytokine level on post-chemotherapy cognitive scores. We found that concentrations of IL-6, MCP-1, sTNFRI, and sTNFRII significantly increased in patients, while IL-1ß significantly decreased (p < 0.05). After controlling for covariates, increases in IL-6 and MCP-1 were associated with worse executive function and verbal fluency in patients from pre- to post-chemotherapy (p < 0.05). Higher baseline IL-6 was associated with better performance on executive function and verbal fluency post chemotherapy (p < 0.05). Overall, these results suggest that chemotherapy-associated increases in cytokines/receptors is associated with worse cognitive function. Larger studies are needed to confirm these findings.


Subject(s)
Antineoplastic Agents/adverse effects , Breast Neoplasms/drug therapy , Cognitive Dysfunction/chemically induced , Cognitive Dysfunction/immunology , Cytokines/immunology , Adult , Aged , Cohort Studies , Cytokines/blood , Female , Humans , Inflammation/chemically induced , Inflammation/immunology , Longitudinal Studies , Middle Aged , Pilot Projects
12.
Neuropharmacology ; 205: 108920, 2022 03 01.
Article in English | MEDLINE | ID: mdl-34902347

ABSTRACT

The 'apple-shaped' anatomical pattern that accompanies visceral adiposity increases risk for multiple chronic diseases, including conditions that impact the brain, such as diabetes and hypertension. However, distinguishing between the consequences of visceral obesity, as opposed to visceral adiposity-associated metabolic and cardiovascular pathologies, presents certain challenges. This review summarizes current literature on relationships between adipose tissue distribution and cognition in preclinical models and highlights unanswered questions surrounding the potential role of tissue- and cell type-specific insulin resistance in these effects. While gaps in knowledge persist related to insulin insensitivity and cognitive impairment in obesity, several recent studies suggest that cells of the neurovascular unit contribute to hippocampal synaptic dysfunction, and this review interprets those findings in the context of progressive metabolic dysfunction in the CNS. Signalling between cerebrovascular endothelial cells, astrocytes, microglia, and neurons has been linked with memory deficits in visceral obesity, and this article describes the cellular changes in each of these populations with respect to their role in amplification or diminution of peripheral signals. The picture emerging from these studies, while incomplete, implicates pro-inflammatory cytokines, insulin resistance, and hyperglycemia in various stages of obesity-induced hippocampal dysfunction. As in the parable of the five blind wanderers holding different parts of an elephant, considerable work remains in order to assemble a model for the underlying mechanisms linking visceral adiposity with age-related cognitive decline.


Subject(s)
Cognitive Dysfunction , Hippocampus , Hyperglycemia , Hyperinsulinism , Inflammation , Obesity, Abdominal , Animals , Cognitive Dysfunction/etiology , Cognitive Dysfunction/immunology , Cognitive Dysfunction/metabolism , Hippocampus/immunology , Hippocampus/metabolism , Hippocampus/physiopathology , Humans , Hyperglycemia/etiology , Hyperglycemia/immunology , Hyperglycemia/metabolism , Hyperinsulinism/etiology , Hyperinsulinism/immunology , Hyperinsulinism/metabolism , Inflammation/etiology , Inflammation/immunology , Inflammation/metabolism , Obesity, Abdominal/complications , Obesity, Abdominal/immunology , Obesity, Abdominal/metabolism
13.
Brain Res Bull ; 180: 1-11, 2022 03.
Article in English | MEDLINE | ID: mdl-34954227

ABSTRACT

Sports-related concussions are particularly common during adolescence, and there is insufficient knowledge about how recurrent concussions in this phase of life alter the metabolism of essential structures for memory in adulthood. In this sense, our experimental data revealed that seven recurrent concussions (RC) in 35-day-old rats decreased short-term and long-term memory in the object recognition test (ORT) 30 days after injury. The RC protocol did not alter motor and anxious behavior and the immunoreactivity of brain-derived neurotrophic factor (BDNF) in the cerebral cortex. Recurrent concussions induced the inflammatory/oxidative stress characterized here by increased glial fibrillary acidic protein (GFAP), interleukin 1ß (IL 1ß), 4-hydroxynonenal (4 HNE), protein carbonyl immunoreactivity, and 2',7'-dichlorofluorescein diacetate oxidation (DCFH) levels and lower total antioxidant capacity (TAC). Inhibited Na+,K+-ATPase activity (specifically isoform α2/3) followed by Km (Michaelis-Menten constant) for increased ATP levels and decreased immunodetection of alpha subunit of this enzyme, suggesting that cognitive impairment after RC is caused by the inability of surviving neurons to maintain ionic gradients in selected targets to inflammatory/oxidative damage, such as Na,K-ATPase activity.


Subject(s)
Brain Concussion , Cognitive Dysfunction , Hippocampus , Memory Disorders , Neuroinflammatory Diseases , Oxidative Stress/physiology , Sodium-Potassium-Exchanging ATPase/metabolism , Spatial Memory/physiology , Age Factors , Animals , Brain Concussion/complications , Brain Concussion/immunology , Brain Concussion/metabolism , Brain Concussion/physiopathology , Cognitive Dysfunction/etiology , Cognitive Dysfunction/immunology , Cognitive Dysfunction/metabolism , Cognitive Dysfunction/physiopathology , Disease Models, Animal , Hippocampus/immunology , Hippocampus/metabolism , Hippocampus/physiopathology , Male , Memory Disorders/etiology , Memory Disorders/immunology , Memory Disorders/metabolism , Memory Disorders/physiopathology , Neuroinflammatory Diseases/etiology , Neuroinflammatory Diseases/immunology , Neuroinflammatory Diseases/metabolism , Neuroinflammatory Diseases/physiopathology , Rats , Rats, Wistar
14.
J Pathol ; 256(3): 262-268, 2022 03.
Article in English | MEDLINE | ID: mdl-34883532

ABSTRACT

Up to 50% of amyotrophic lateral sclerosis patients present with cognitive deficits in addition to motor dysfunction, but the molecular mechanisms underlying diverse clinical and pathological presentations remain poorly understood. There is therefore an unmet need to identify molecular drivers of cognitive dysfunction to enable better therapeutic targeting and prognostication. To address this, we employed a non-biased approach to identify molecular targets using a deeply phenotyped, clinically stratified cohort of cognitively affected and unaffected brain regions from three brain regions of 13 amyotrophic lateral sclerosis patients with the same cognitive screening test performed during life. Using NanoString molecular barcoding as a sensitive mRNA sequencing technique on post-mortem tissue, we profiled a data-driven panel of 770 genes using the Neuropathology Panel, followed by region and cell type-specific validation using BaseScope in situ hybridisation and immunohistochemistry. We identified 50 significantly dysregulated genes that are distinct between cognitively affected and unaffected brain regions. Using BaseScope in situ hybridisation, we also demonstrate that macromolecular complex regulation, notably NLRP3 inflammasome modulation, is a potential, therapeutically targetable, pathological correlate of cognitive resilience in ALS. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd on behalf of The Pathological Society of Great Britain and Ireland.


Subject(s)
Amyotrophic Lateral Sclerosis/genetics , Brain/immunology , Cognition , Cognitive Dysfunction/genetics , Inflammasomes/genetics , NLR Family, Pyrin Domain-Containing 3 Protein/genetics , Resilience, Psychological , Amyotrophic Lateral Sclerosis/immunology , Amyotrophic Lateral Sclerosis/physiopathology , Amyotrophic Lateral Sclerosis/radiotherapy , Brain/physiopathology , Cognitive Dysfunction/immunology , Cognitive Dysfunction/physiopathology , Cognitive Dysfunction/psychology , Gene Expression Profiling , Humans , Inflammasomes/immunology , NLR Family, Pyrin Domain-Containing 3 Protein/immunology , Transcriptome
15.
J Immunol Res ; 2021: 5578958, 2021.
Article in English | MEDLINE | ID: mdl-34869782

ABSTRACT

BACKGROUND: As a transitional state between normal aging and Alzheimer's disease (AD), mild cognitive impairment (MCI) is characterized by a worse cognitive decline than that of natural aging. The association between AD and gut microbiota has been reported in a number of studies; however, microbial research regarding MCI remains limited. METHODS: This study examined 48 participants, of whom 22 were MCI cases and 26 were normal control cases. Fecal samples were collected for 16S ribosomal RNA (rRNA) quantitative arrays and bioinformatics analysis. RESULTS: A principal coordinates analysis (PCoA) and nonmetric multidimensional scaling (NMDS) both demonstrated that the microbial composition of participants with MCI deviated from that of healthy control participants. Multiple bacterial species were significantly increased (e.g., Staphylococcus intermedius) or decreased (e.g., Bacteroides salyersiae) in samples from the MCI group. CONCLUSION: The composition of gut microbiota differed between normal control and MCI cases. This is the first study to identify a signature series of species in the gut microbiota of individuals with MCI. The results provide a new direction for the future development of an early diagnosis and probiotic regimen.


Subject(s)
Aging/immunology , Cognitive Dysfunction/immunology , Dysbiosis/complications , Gastrointestinal Microbiome/immunology , Aged , Case-Control Studies , Cognitive Dysfunction/microbiology , Cognitive Dysfunction/prevention & control , Dysbiosis/diet therapy , Dysbiosis/immunology , Dysbiosis/microbiology , Feces/microbiology , Female , Healthy Volunteers , Humans , Male , Middle Aged , Probiotics/administration & dosage
16.
Nat Commun ; 12(1): 6810, 2021 11 23.
Article in English | MEDLINE | ID: mdl-34815409

ABSTRACT

The prefrontal-hippocampal dysfunction that underlies cognitive deficits in mental disorders emerges during early development. The lateral entorhinal cortex (LEC) is tightly interconnected with both prefrontal cortex (PFC) and hippocampus (HP), yet its contribution to the early dysfunction is fully unknown. Here we show that mice that mimic the dual genetic (G) -environmental (E) etiology (GE mice) of psychiatric risk have poor LEC-dependent recognition memory at pre-juvenile age and abnormal communication within LEC-HP-PFC networks throughout development. These functional and behavioral deficits relate to sparser projections from LEC to CA1 and decreased efficiency of axonal terminals to activate the hippocampal circuits in neonatal GE mice. In contrast, the direct entorhinal drive to PFC is not affected, yet the PFC is indirectly compromised, as target of the under-activated HP. Thus, the entorhinal-hippocampal circuit is already impaired from neonatal age on in GE mice.


Subject(s)
CA1 Region, Hippocampal/physiopathology , Cognitive Dysfunction/physiopathology , Entorhinal Cortex/physiopathology , Mental Disorders/physiopathology , Prefrontal Cortex/physiopathology , Animals , Animals, Newborn , Cognitive Dysfunction/genetics , Cognitive Dysfunction/immunology , Disease Models, Animal , Female , Gene-Environment Interaction , Humans , Male , Mental Disorders/genetics , Mental Disorders/immunology , Mice , Mice, Transgenic , Nerve Tissue Proteins/genetics , Neural Pathways/physiopathology , Optogenetics , Patch-Clamp Techniques , Pregnancy
17.
J Integr Neurosci ; 20(3): 541-549, 2021 Sep 30.
Article in English | MEDLINE | ID: mdl-34645087

ABSTRACT

Executive processes that predominantly effect people living with human immunodeficiency virus remain to be understood. In the present case-control study, components summarizing executive functions were empirically determined to clarify the nature of executive difficulties observed in individuals with human immunodeficiency virus. One hundred and five seropositive and 62 seronegative healthy adults without comorbidities underwent a comprehensive executive function assessment. Test data were reduced via principal components analysis and component scores were used to investigate whether seropositive adults exhibit selective difficulties in specific executive processes. A three-component solution was found, consisting of updating, inhibition and set-shifting. Group differences between seropositive and seronegative participants were observed only in the updating component. In the present exploratory analyses, significant findings emerged that suggest a selective executive impairment associated with the updating/working memory process in young to middle adulthood seropositive individuals without comorbidities.


Subject(s)
Cognitive Dysfunction , Executive Function/physiology , HIV Infections , Memory, Short-Term/physiology , Adult , Case-Control Studies , Cognitive Dysfunction/etiology , Cognitive Dysfunction/immunology , Cognitive Dysfunction/physiopathology , HIV Infections/complications , HIV Infections/immunology , HIV Infections/physiopathology , Humans , Middle Aged , Neuropsychological Tests , Principal Component Analysis , Young Adult
18.
Aging (Albany NY) ; 13(18): 22092-22108, 2021 09 29.
Article in English | MEDLINE | ID: mdl-34587117

ABSTRACT

In order to understand the long-term effects of systemic inflammation, it is important to distinguish inflammation-induced changes in baseline cognitive function from changes that interact with aging to influence the trajectory of cognitive decline. Lipopolysaccharide (LPS; 1 mg/kg) or vehicle was administered to young adult (6 months) male rats via intraperitoneal injections, once a week for 7 weeks. Longitudinal effects on cognitive decline were examined 6 and 12 months after the initial injections. Repeated LPS treatment, in adults, resulted in a long-term impairment in memory, examined in aged animals (age 18 months), but not in middle-age (age 12 months). At 12 months following injections, LPS treatment was associated with a decrease in N-methyl-D-aspartate receptor-mediated component of synaptic transmission and altered expression of genes linked to the synapse and to regulation of the response to inflammatory signals. The results of the current study suggest that the history of systemic inflammation is one component of environmental factors that contribute to the resilience or susceptibility to age-related brain changes and associated trajectory of cognitive decline.


Subject(s)
Aging/immunology , Aging/psychology , Cognitive Dysfunction/immunology , Aging/genetics , Animals , Behavior, Animal , Cognition , Cognitive Dysfunction/genetics , Cognitive Dysfunction/physiopathology , Cognitive Dysfunction/psychology , Hippocampus/immunology , Hippocampus/metabolism , Hippocampus/physiopathology , Humans , Male , Memory, Long-Term , Rats , Rats, Inbred F344 , Receptors, N-Methyl-D-Aspartate/genetics , Receptors, N-Methyl-D-Aspartate/immunology , Synapses/genetics , Synapses/immunology , Synaptic Transmission
19.
Neurosci Lett ; 764: 136202, 2021 11 01.
Article in English | MEDLINE | ID: mdl-34478817

ABSTRACT

Cerebral ischemia is a major health threat to humankind around the world, and the reperfusion methods may provoke irreversible damages to brain tissues, causing impairment of neurological function. The goal of this study is to investigate the potential neurological protective effect of PJ34, a well-characterized poly (ADP-ribose) polymerase 1 (PARP-1) inhibitor, on cerebral ischemia-reperfusion (I/R)-induced injury of the rat model. The cerebral I/R rats were received (3, 6, or 12 mg/kg) injections of PJ34 or saline at 24 h, 6 h before middle cerebral artery occlusion (MCAO) and 1 h, 24 h, and 48 h after MCAO. All rats were subject to the neurological behavior tests by open field test and Morris water maze test. The expression of pro-inflammatory cytokines, Cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) in cerebral tissues was also determined. Our results demonstrated that the administration of PJ34 dose-dependently ameliorated cerebral I/R-induced injury and improved neurological performance of cerebral I/R rats. We also revealed that PJ34 treatment effectively reduced COX2, iNOS, and pro-inflammatory cytokine levels in the I/R-induced injury tissues. Our finding further supports that inhibition of PARP-1 activity is beneficial for reducing post-I/R-induced brain damage via targeting inflammatory response.


Subject(s)
Cognitive Dysfunction/drug therapy , Ischemic Attack, Transient/complications , Phenanthrenes/administration & dosage , Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage , Reperfusion Injury/drug therapy , Animals , Brain/blood supply , Brain/drug effects , Brain/immunology , Brain/pathology , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/immunology , Cognitive Dysfunction/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Humans , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/metabolism , Ischemic Attack, Transient/drug therapy , Ischemic Attack, Transient/immunology , Ischemic Attack, Transient/pathology , Male , Morris Water Maze Test/drug effects , Poly (ADP-Ribose) Polymerase-1/antagonists & inhibitors , Poly (ADP-Ribose) Polymerase-1/metabolism , Rats , Reperfusion Injury/immunology , Reperfusion Injury/pathology
20.
PLoS One ; 16(9): e0256972, 2021.
Article in English | MEDLINE | ID: mdl-34473764

ABSTRACT

High titers of anti-NMDAR1 autoantibodies in brain cause anti-NMDAR1 encephalitis that displays psychiatric symptoms of schizophrenia and/or other psychiatric disorders in addition to neurological symptoms. Low titers of anti-NMDAR1 autoantibodies are reported in the blood of a subset of the general human population and psychiatric patients. Since ~0.1-0.2% of blood circulating antibodies cross the blood-brain barriers and antibodies can persist for months and years in human blood, it is important to investigate whether chronic presence of these blood circulating anti-NMDAR1 autoantibodies may impair human cognitive functions and contribute to the development of psychiatric symptoms. Here, we generated mice carrying low titers of anti-NMDAR1 autoantibodies in blood against a single antigenic epitope of mouse NMDAR1. Mice carrying the anti-NMDAR1 autoantibodies are healthy and display no differences in locomotion, sensorimotor gating, and contextual memory compared to controls. Chronic presence of the blood circulating anti-NMDAR1 autoantibodies, however, is sufficient to impair T-maze spontaneous alternation in the integrity of blood-brain barriers across all 3 independent mouse cohorts, indicating a robust cognitive deficit in spatial working memory and/or novelty detection. Our studies implicate that chronic presence of low titers of blood circulating anti-NMDAR1 autoantibodies may impair cognitive functions in both the general healthy human population and psychiatric patients.


Subject(s)
Autoantibodies/blood , Autoantibodies/immunology , Cognition , Cognitive Dysfunction/blood , Cognitive Dysfunction/immunology , Nerve Tissue Proteins/immunology , Receptors, N-Methyl-D-Aspartate/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Behavior, Animal , Blood-Brain Barrier/immunology , Freund's Adjuvant/administration & dosage , Locomotion/immunology , Male , Memory, Short-Term , Mice , Mice, Inbred C57BL , Models, Animal , Mycobacterium tuberculosis/immunology , Nerve Tissue Proteins/chemistry , Peptides/administration & dosage , Peptides/immunology , Receptors, N-Methyl-D-Aspartate/chemistry , Spatial Memory , Vaccination/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...